Royalty Pharma now expects 2023 Adjusted Cash Receipts(1) (non-GAAP) to be between $2,850 million and $2,950...
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the...
00018027682022FYFALSEhttp://fasb.org/us-gaap/2022#AccountingStandardsUpdate201613Memberhttp://fasb.org/us-gaap/2...
0001802768false00018027682023-02-152023-02-15UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 8-K CURRENT REPORTPursuant...
Net cash provided by operating activities (GAAP) of $570 million and Adjusted Cash Receipts(1) (non-GAAP) of...
NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will...
SCHEDULE 13G Amendment No.2 ROYALTY PHARMA PLC CLASS A COMMON STOCK Cusip #G7709Q104 Check the appropriate box to...
SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934(Amendment No.: 1)* Name...
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the...
NEW YORK, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will...
2022 Net cash provided by operating activities (GAAP) expected to be approximately $2,140 million to $2,150...
Royalty Pharma to acquire an interest in SPINRAZA® and pelacarsen royalties – Ionis retains majority of...
Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic...
NEW YORK, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board...
NEW YORK, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will present at the 41st Annual J.P...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.